Blockade of chemokine signaling in patients with multiple sclerosis

F. Zipp, H. P. Hartung, J. Hillert, S. Schimrigk, C. Trebst, M. Stangel, C. Infante-Duarte, P. Jakobs, C. Wolf, R. Sandbrink, C. Pohl, M. Filippi

Research output: Contribution to journalArticlepeer-review


We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.

Original languageEnglish
Pages (from-to)1880-1883
Number of pages4
Issue number10
Publication statusPublished - Nov 2006

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Blockade of chemokine signaling in patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this